StemDAO is engineering mesenchymal stem cells (MSCs) to adopt an anti-inflammatory phenotype, optimizing their exosomes and secretome for therapeutic use. These extracellular vesicles (EVs) target age-related decline, leveraging research from Gadi Turgeman’s lab at Ariel University, Israel.
Based on strong preclinical data and insights from global research over the past decade, we have identified three key therapeutic targets:
Our proprietary polarized MSC-derived EVs modulate neuroinflammation, enhance neurogenesis, and improve cognitive function. Out preclinical data shows that intranasal administration of these EVs improves spatial learning and memory in aged mice, with selective targeting of inflamed brain regions.
Our MSC-derived EVs reverse senescence-associated fibroblast dysfunction. When combined with microneedling, these EVs can penetrate deeper into the skin, enhancing wound healing and elasticity. This approach provides a fast track for clinical translation in aesthetic and dermatological applications.
EVs from young tissues reduce systemic inflammation and cellular senescence, which drive multi-organ dysfunction in aging. Preclinical data show lifespan extension and improved immune homeostasis following EV infusion in mice. StemDAO develops polarized MSC-derived EVs for intravenous administration, targeting inflammatory and metabolic aging pathways.
To establish this therapy as a viable product, we are focused on:
Multi-omics characterization of EV bioactive components.
Optimizing the therapies, refining their regenerative potential for human trials.
Development of reproducible, cost-effective production methods for large-scale EV generation.
Further validation in aging models to assess systemic effects and therapeutic potential.
Deployment through grey market access, special jurisdiction approvals, and medical tourism to accelerate availability.
A plan to use the will of the crypto community to create a revolutionary stem cell product for the world
Activate first production run
On senotherapeutic, anti-inflammatory and neurogenesis effects in mice
IRB complete and Trial protocols drafted
Pre clinical data in
Approved trial
Stem cell and extracellular vesicle (EV) therapies are reshaping regenerative medicine. Thousands of clinics worldwide offer these treatments, with patients traveling across the globe to access them—often paying tens of thousands of dollars for a single procedure. Yet, despite promising preclinical and clinical outcomes, regulatory barriers have stalled approval in major markets like the U.S., forcing these therapies into a fragmented grey market.
StemDAO exists to accelerate access to high-quality regenerative treatments by advancing the development of clinically validated, standardized, and ethically governed therapies. We focus on stem cell-derived EVs, secretomes, and related modalities—leveraging their unique ability to repair, regenerate, and enhance cellular function.
Over the past decade, stem cells and EVs derived from them and from peripheral blood have demonstrated remarkable effects across a wide range of conditions, from brain and heart regeneration to wound healing and longevity extension. Stem cell-based can integrate into aged or damaged tissues and promote regeneration and rejuvenation. Similarly, EVs - the tiny, bioactive particles secreted by cells - carry regenerative signals capable of modulating immune function, reducing inflammation, and promoting tissue repair.
Studies have shown that infusions of young stem cells or EVs can improve cognitive function, heart health, liver regeneration, and even extend lifespan. Notably, research suggests that the parabiosis effect - where young blood rejuvenates aged tissues - may be partially mediated by EVs, highlighting their potential for age-related therapies.
Despite these promising breakthroughs, bringing stem cell and EV therapies into mainstream medicine faces significant challenges.
Differences in how and from what batches stem cells and EVs are derived lead to inconsistent treatment outcomes.
Unlike traditional pharmaceuticals, these therapies involve thousands of bioactive molecules, making regulatory approval difficult.
Current classification standards fail to fit the unique nature of cell-derived treatments, limiting their adoption.
Many treatments exist in anecdotal and uncontrolled settings, reducing their credibility in the medical community.
StemDAO is addressing these challenges by developing standardized, clinically validated regenerative therapies that meet the highest scientific and ethical standards. Through decentralized governance, global clinical collaborations, and AI-driven analytics, we are unlocking the full potential of stem cell-derived EVs for targeted therapeutic applications.new
